CA-GUESS?
27.7.2022 17:02:14 CEST | Business Wire | Press release
In collaboration with Homeboy Industries, GUESS has developed a unique process to give new life to old clothing. By transforming recycled pieces into fun, fashionable creations, GUESS is building a new pathway to being fabulously sustainable. Sustainability is at the heart of all that GUESS does, and the Company’s partnership with the non‐profit Homeboy Industries represents this commitment.
GUESS will work directly with Homeboy Recycling, a social enterprise branch of Homeboy Industries on the new Upcycled Collection. In partnering with GUESS, Homeboy Recycling has expanded from exclusively electronics recycling into the world of textiles and apparel. GUESS and Homeboy Recycling have created not only a remarkable new line of goods and apparel, but a new way to support environmental sustainability, facilitate creativity, create new jobs, and uplift our community: upcycled with a whole lot of heart.
It is with absolute pride that GUESS announces the Upcycled Collection. A collection unlike any other, because no two pieces are alike. Transforming recycled clothing yields distinctly unique pieces, and that is its ultimate appeal. Tote bags, patchwork denim, bustiers, and even throw pillows; upcycled fashion for everyone. The Upcycled Collection is a sustainable, fashionable, purposeful way to shop‐the truest form of circular fashion.
“Homeboy Industries is grateful for the partnership with GUESS for the Upcycled Collection. We thank GUESS for supporting our mission to provide hope, training, and support to this marginalized population, allowing them to change the arc of their lives and become contributing members of the community. Homeboy Industries provides comprehensive trauma‐informed, wrap‐around support services such as tattoo removal, mental health services, education, legal, housing navigation, case management, workforce development, and job training,” says Chris Zwicke, CEO of Homeboy Industries. “Through this partnership, our employees at our fastest growing social enterprise, Homeboy Recycling, will gain more job skills and training, which we are very excited about.”
“The Upcycled Collection in collaboration with Homeboy Industries is designed with the hope that each piece can give purpose to a member of the community who can learn the skills needed to turn discarded merchandise into desirable, commodified items with an eye to the fashion set. The designs are determined by the resources at hand, which are carefully organized and sorted. The product range is fashion to non‐fashion pieces, so there is something for everyone. And the true joy is the wonderment around the former life of each piece and how it came to be,” says Amy Enuke, Young Contemporary Design Director.
With GUESS’ commitment to circular fashion and Homeboy Recycling’s foundation of sustainability, this partnership is the launching pad for a new kind of sustainable fashion—one that not only supports the environment but also directly supports our communities. To learn more about GUESS’ commitment to our planet, visit guess.com/sustainability
About GUESS?, Inc.
Established in 1981, GUESS began as a jeans company and has since successfully grown into a global lifestyle brand. Guess?, Inc. designs, markets, distributes and licenses a lifestyle collection of contemporary apparel, denim, handbags, watches, eyewear, footwear and other related consumer products. Guess? products are distributed through branded Guess? stores as well as better department and specialty stores around the world. As of April 30, 2022, the Company directly operated 1,073 retail stores in the Americas, Europe and Asia. The Company’s partners and distributors operated 565 additional retail stores worldwide. As of April 30, 2022, the Company and its partners and distributors operated in approximately 100 countries worldwide. For more information about the Company, please visit www.guess.com.
About Homeboy Recycling
Homeboy Recycling is a certified and award-winning social enterprise offering nationwide services for the proper disposal and management of IT assets. As one of the few R2 (Responsible Recycling) and B Corp certified companies in the world, Homeboy is committed to the highest possible standards for electronics reuse, e-waste recycling and the destruction of sensitive data. Each year, Homeboy refurbishes thousands of computers and diverts millions of pounds of electronics away from the landfill while creating jobs for people facing systemic barriers to employment. Beyond our IT asset disposition and e-waste services, we see ourselves broadly as a partner in the circular economy. We work with committed manufacturers and brands to develop socially and environmentally beneficial solutions for their products after their first life. In this capacity, we are expanding our services to include apparel/textiles and other products/materials that fit our mission.
As part of Homeboy Industries, the world’s preeminent gang rehabilitation and re-entry program, Homeboy Recycling proudly employs people committed to transforming their lives after incarceration. For more information, visit https://homeboyrecycling.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220727005664/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
